iOnctura to present research at leading scientific conferences in June 2023

iOnctura to present research at leading scientific conferences in June 2023

Geneva, Switzerland and Amsterdam, The Netherlands, 1 June 2023 - iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.

The iOnctura team will present the Company’s research on its first-in-class, non-ATP-competitive, allosteric modulator of PI3Kδ, roginolisib.

American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA

2-6 June 2023

Poster title: ‘First-in-human (FIH) phase I dose escalation study (Part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in Uveal Melanoma (Part B)’

Presentation Time: 3 June 2023 at 08:00-11:00 CDT

European Hematology Association (EHA) Hybrid Congress, Frankfurt, Germany

8-16 June 2023

Poster title: ‘Highly selective allosteric modulator of the phosphoinositide 3-kinase data (PI3Kδ) roginolisib (IOA-244) in a dose escalation study of patients with refractory/relapsed follicular lymphoma (FL)’

Presentation Time: 10 June 2023 at 16:30-17:45 CEST

European Association for Cancer Research (EACR) Congress 2023, Torino, Italy

12-15 June 2023

Poster title: ‘Patient derived tumor cells identify mechanistically rational combinations for the PI3Kδ inhibitor roginolisib in solid and hematologic malignancies’

Presentation Time: 14 June 2023 at 11:00-18:00 CEST.

International Conference on Malignant Lymphoma, Lugano, Switzerland

13-17 June 2023

Poster title: ‘Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) Roginolisib In Patients With Refractory/Relapsed Follicular Lymphoma’

Presentation Time: 15 June 2023 at 12:30-13:00 CEST

Michael Lahn, Chief Medical Officer of iOnctura, said: “As our lead therapeutic candidates advance through the clinic, we are excited to be sharing our research developments with the scientific community. We are excited about the recent clinical observations for roginolisib as well as for IOA-289. Roginolisib overcomes cancer-induced immune suppression by re-balancing the immune cell subsets and thus enables patients to fight cancer. Because this process occurs in other malignancies, we expect that our findings will have an application in tumor types other than uveal melanoma. ”

If you would like to meet with the iOnctura team, please contact us using the details provided below. For more information, please visit us at https://www.ionctura.com/

For more information contact:

iOnctura

Catherine Pickering

Chief Executive Officer

T : +41 79 952 72 52

E: c.pickering@iOnctura.com